The present invention provides a labeling method for improving signal intensity of time-resolved fluorescence; and the labeling method can be applied in the detection of olaquindox or gentamicin. The olaquindox antibody complex immunolabelled by time-resolved fluorescence prepared in the present invention has a more stable structure, stronger fluorescence signal, and higher detection sensitivity.

The present invention provides a labeling method for improving signal intensity of time-resolved fluorescence; and the labeling method can be applied in the detection of olaquindox or gentamicin. The olaquindox antibody complex immunolabelled by time-resolved fluorescence prepared in the present invention has a more stable structure, stronger fluorescence signal, and higher detection sensitivity.

A molecular nanotag is disclosed that includes a core nanoparticle with a diameter of less than about 100 nm, with an optional shell surrounding the core, and an armor bound to the surface of the core nanoparticle, or if present, to the surface of the shell. The molecular nanotag also includes a functionalized end with a fixed number of binding sites that can selectively bind to a molecular targeting ligand. Any one of, or any combination of, the core, the shell and the armor contribute to fluorescence, light scattering and/or ligand binding properties of the molecular tag that are detectable by microscopy or in a devices that measures intensity or power of fluorescence and light scattering. The light scattering intensity or power of the assembled structure is detectable above the specific level of the reference noise of a device detecting the light scattering intensity or power, its fluorescence intensity or power has sufficient brightness for detection above the limit of detection for the instrument, and ligand specificity is conferred by the ligand binding component. Methods of biomarker and biosignature detection using the molecular tags are also disclosed.

The present invention provides silica shell encapsulated polyaromatic-core microparticles and methods for producing and using the same. In particular, the silica shell encapsulated polyaromatic-core microparticles of the invention are hydrophilic microparticle scintillators comprising (i) polyaromatic-core microparticle (1), wherein said polyaromatic-core microparticle (1) is doped with a scintillator material (2); and (ii) a silica-shell portion (3) encapsulating said polyaromatic-core microparticle (1), wherein said silica-shell portion (3) comprises an outer surface (4). The polyaromatic-core portion is formed from an aromatic vinyl compound selected from the group consisting of styrene, vinyl toluene, and a mixture thereof.

The present invention provides silica shell encapsulated polyaromatic-core microparticles and methods for producing and using the same. In particular, the silica shell encapsulated polyaromatic-core microparticles of the invention are hydrophilic microparticle scintillators comprising (i) polyaromatic-core microparticle (1), wherein said polyaromatic-core microparticle (1) is doped with a scintillator material (2); and (ii) a silica-shell portion (3) encapsulating said polyaromatic-core microparticle (1), wherein said silica-shell portion (3) comprises an outer surface (4). The polyaromatic-core portion is formed from an aromatic vinyl compound selected from the group consisting of styrene, vinyl toluene, and a mixture thereof.

The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

An object of the present invention is to provide a kit, a method, and a reagent which prevent the problem of false positive due to nonspecific adsorption, suppress the increase in noise to be generated, and are capable of achieving high-precision measurement of a measurement target substance in a wide concentration range from a low concentration to a high concentration. According to the present invention, there is provided a kit for measuring a measurement target substance, the kit including: a first particle having a label and modified with a first binding substance; a second particle having no label and modified with a second binding substance; a flow channel for flowing the first particle and the second particle; and a substrate having a third binding substance capable of specifically binding to the measurement target substance or a substance capable of binding to the first binding substance, in which the first particle having a label is a luminescent labeled particle containing at least one kind of compound represented by Formula (1) and a particle. ##STR00001## Each symbol in Formula (1) has the meaning described in the present specification.

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions. ##STR00001##

Provided is a method for analyzing a tissue specimen, including treating a tissue specimen with an aqueous clearing agent and with at least two fluorescent probes to obtain a cleared and labeled tissue specimen; imaging the cleared and labeled tissue specimen to generate a three-dimensional (3D) image of the tissue specimen; preparing a stained tissue section from the cleared and labeled tissue specimen; capturing a reference two-dimensional (2D) image of the stained tissue section; matching the reference 2D image with the 3D image to extract from the 3D image a series of 2D image slices including a corresponding 2D image slice that corresponds to the reference 2D image; and determining at least one pathological score for each of the series of 2D image slices and reporting the presence or absence and the extent of the disease based on the pathological scores. The method can improve the accuracy of histopathologic diagnosis.

Provided is a method for analyzing a tissue specimen, including treating a tissue specimen with an aqueous clearing agent and with at least two fluorescent probes to obtain a cleared and labeled tissue specimen; imaging the cleared and labeled tissue specimen to generate a three-dimensional (3D) image of the tissue specimen; preparing a stained tissue section from the cleared and labeled tissue specimen; capturing a reference two-dimensional (2D) image of the stained tissue section; matching the reference 2D image with the 3D image to extract from the 3D image a series of 2D image slices including a corresponding 2D image slice that corresponds to the reference 2D image; and determining at least one pathological score for each of the series of 2D image slices and reporting the presence or absence and the extent of the disease based on the pathological scores. The method can improve the accuracy of histopathologic diagnosis.